




klinik utama

**simas sehat** 

# DEVELOPING PERSONALIZED CANCER TESTS

Imagine a cancer treatment plan  
*as unique as your DNA*



## ABOUT US

RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient's genes.

Working from our world-leading laboratories in Europe, using world-leading technology, equipment and innovative techniques, our team of scientists have developed a range of tests that give healthcare professionals comprehensive information about a patient's genetics, physiology and immune profiles. This diversion from a 'one-size-fits all approach' uses data to determine what treatment



RGCC is a global organisation that collaborates with branch offices and distributors to provide a worldwide service.

Our head office is located in Switzerland and we have state of the art laboratory facilities based around the world.



# ABOUT RGCC TESTS

Our range of tests can detect circulating tumor cells and circulating free DNA in the blood, and it's designed to discover, analyze and screen cancer cells at every step of the disease, and to provide vital information that can help clinicians to identify the best, and most effective, cancer treatments and therapies.



## Who should consider getting tested?

- ✓ Individuals who wish to incorporate his test into their annual body check.
- ✓ Individuals who have a family history of cancer.
- ✓ Cancer patients who wish to track their progress and obtain insight regarding their potential response to various therapeutic treatments.

**96.000+**  
tests done  
so far

**80.000+**  
patient  
served

**50**  
types of natural  
substances  
tested

**100+**  
types of  
therapeutic  
drugs tested


## 3 steps to getting RGCC test



**STEP 1**  
Arrange an  
appointment



**STEP 2**  
Visit your doctor for a  
blood sample



**STEP 3**  
Report will be ready in  
3 weeks

# Advantages of the RGCC Test



## Non-invasive

A blood test that requires no surgical intervention



## Highly personalized

Diversification from a one-size-fits-all



## Help determine risk

Insight to tell the risk of the cancer spreading or returning



## Help determine therapeutic effectiveness

Insight to help determine whether particular therapies are effective



## As monitoring tool

Help to monitor a patient's progress



## High sensitivity & specificity

87% sensitivity & 83% specificity



## Helping you make informed decisions and formulate effective treatment plans

A blood test for patients seeking personalized cancer testing with high sensitivity and specificity, where it has the ability to:

1

Detect early signs of developing cancer

2

Help monitor existing cancers


3

Produce an individual profile of chemotherapeutic drugs and natural substances that can be used as insight to achieve best treatment outcomes




# Our Technology

At RGCC, we embrace innovation leveraging cutting-edge testing technology.



We isolate the CTCs using a technology called flow cytometry in order to obtain a sample of 97-99% pure cells that are 99% viable for further testing, such as molecular analysis, immuno-phenotyping, gene expression assays, and sensitivities to various agents.


## What is Circulating Tumor Cell?




Circulating Tumor Cell (CTC) tests detect CTCs in the blood or lymph. CTCs are cells that have detached from the original tumor and passed into the blood, the lymph system, or another part of the body, with the potential to create a secondary tumor.

# RGCC tests **VS** Other cancer tests

Cost-effective and highly accurate tests will give you the information you need to formulate effective personalized treatment plans.



Other brand tests



RGCC tests



# RGCC TESTS



- Oncotrace



- Oncotrail



- Onconomics Extracts<sup>+</sup>



- Onconomics Plus



- Array Comparative Genomic Hybridization (aCGH)




- Immune-Frame



- Metastat



- ChemoSNiP



## Oncotrace RGCC

Oncotrace RGCC is used to identify a primary tumor in a patient and to provide guidance about disease progression and future prognosis. During the test, a sample of blood is analyzed to identify the presence and concentration of circulating tumor cells (CTCs) and their concentration.

This test provides information about the presence of CTCs, their concentration and their specific type (immunophenotype) and CSC (Cancer Stem Cell).

The results of the test enable clinicians to identify the origin of a tumor where this is unknown and to provide information on the development of cancer and the prognosis.

### Sample Type

Blood sample



### Cancer Type

All types of Cancers



### Sample Size



### Analysis Period

Approx.  
7 days




### Final Results

7–10 days  
\*since the sample  
has been properly  
received at the  
RGCC laboratory



7–10 ml peripheral  
whole blood





## Oncotrail RGCC

**Oncotrail RGCC** provides crucial information on the presence of **circulating tumour cells (CTCs)** and their concentration in patients who have a **confirmed diagnosis of specific forms of cancer**, including **breast, colon and prostate cancer**.

During the test, a sample of blood is analysed to identify the presence and concentration of **CTC** and their **immunophenotype**.

Oncotrail RGCC isn't used as a primary diagnostic test to confirm a cancer diagnosis, but provides essential information on the effectiveness of current cancer treatments. Follow-up tests can also be used to monitor a patient's health and assess the risk of relapse.

### Sample Type

Blood sample



### Cancer Type

All types of Cancers



### Sample Size



### Analysis Period

Approx.  
7 days



### Final Results

7–10 days  
\*since the sample  
has been properly  
received at the  
RGCC laboratory



7–10 ml peripheral  
whole blood



## Onconomics Extracts<sup>+</sup>

**Onconomics Extracts<sup>+</sup>** provides highly detailed and accurate information about how effective specific **natural substances and plant extracts** are, as anticancer agents as well as the gene expression profile of genes, associated with fundamental biological processes. This includes processes such as angiogenesis, cell cycle regulation, self-repair, metastasis, apoptosis, proliferation etc.

Circulating tumor cells are isolated from a peripheral blood sample and then used for different assays. The results provide a **comprehensive and highly personalized analysis of the most effective natural treatments** that patients can use to treat their cancer, alongside conventional therapies.

**Natural substances and extracts that are tested are divided into Class-I (Cytotoxic agents), Class-II (Immunostimulants / immunomodulators), and Class-III (PK inhibitors).**

### Sample Type

Blood sample



### Cancer Type

All types of cancer. Specific sample requirements for CNS



### Sample Size



### Analysis Period

Approx.  
7 days



### Final Results

7-10 days  
\*since the sample has been properly received at the RGCC laboratory



15-25 ml peripheral whole blood  
Tissue sample qty:  
Minimum 400mg





# Onconomics Plus RGCC

**Onconomics Plus** RGCC provides information about the **effect of specific anti-cancer drugs, targeted therapies and natural treatments** on the cancer cells in an individual patient.

During the test, a sample of blood or tissue is analyzed to test how effective specific therapies and treatments are at suppressing cancer.

Together, the results of the extensive tests provide scientists and clinicians with a comprehensive breakdown of the most suitable and successful treatments for cancer. The results can be used by clinicians to design personalized and targeted cancer therapies with the highest chances of success.

## Sample Type

Blood sample



## Cancer Type

All types of cancer. Specific sample requirements for CNS



## Sample Size



## Analysis Period

Approx.  
7 days




## Final Results

7-10 days  
\*since the sample has been properly received at the RGCC laboratory



15-25 ml peripheral whole blood  
Tissue sample qty:  
Minimum 400mg



# Array Comparative Genomic Hybridisation (aCGH) RGCC

The Array Comparative Genomic Hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer. During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome.

This insight enables them to assess the likely risk of cancer developing and the potential location of a primary tumour. aCGH RGCC can help clinicians to understand more about a patient's genes, giving them a powerful tool in the fight against cancer.

## Sample Type

Blood sample



## Cancer Type

All types of Cancers



## Sample Size



## Analysis Period

Approx.  
2–3 weeks




## Final Results

3–4 weeks  
\*since the sample  
has been properly  
received at the  
RGCC laboratory



7–10 ml peripheral  
whole blood





# Immune-Frame

Immune-Frame is used to assess the condition of a patient's immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient's immune system on and off.

The results of Immune-Frame can be used to analyse the status of a patient's immune system, and to provide ongoing information about their health status. This information can be used by clinicians to advise on potential health risks a patient may face, and how these can be minimised.

## Sample Type

Peripheral  
whole  
blood



## Cancer Type

All types of  
Cancers



## Sample Size



15–25 ml peripheral  
whole blood

## Analysis Period


Approx.  
7 days



## Final Results

7–10 days  
\*since the sample  
has been properly  
received at the  
RGCC laboratory





## Metastat RGCC

**Metastat RGCC** is an advanced test to detect specific blood borne markers that can accurately determine whether a secondary cancerous tumor is likely to develop and its potential location.

During the test, we analyze a sample of a patient's blood in our state of the art laboratory to analyze, identify and measure circulating tumor cells (CTCs).

Metastat RGCC is suitable for all patients who have received a confirmed cancer diagnosis. The test can accurately detect the **development of secondary cancers** or tumors and improve personalized cancer treatments.

### Sample Type

Peripheral  
whole  
blood



### Cancer Type

All types of  
Cancers



### Sample Size



### Analysis Period

Approx.  
7 days



### Final Results

7-10 days  
\*since the sample  
has been properly  
received at the  
RGCC laboratory



7-10 ml peripheral  
whole blood





## ChemoSNiP RGCC

**ChemoSNiP** is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyze how a patient's body will respond to a specific drug.

ChemoSNiP analyses a blood sample to identify single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments with chemicals, drugs and other agents.

ChemoSNiP provides clinicians with a powerful insight into **which drugs are most effective** at treating cancer. The results provide a personalized analysis that can be used to provide the most effective combination of drugs and treatments available.

### Sample Type

Buccal swabs or peripheral whole blood



### Cancer Type

All types of cancer. Specific sample requirements for CNS



### Sample Size



### Analysis Period

Approx. 7 days



### Final Results

7–10 days  
\*since the sample has been properly received at the RGCC laboratory



15–25 ml peripheral whole blood  
Tissue sample qty: Minimum 400mg



**RGCC is accredited and monitored for compliance by the International Accreditation Service (IAS) to ISO/IEC Standard 17025 for testing laboratories.**



## **RGCC INDONESIA** **Klinik Simas Sehat**

Address : Plaza Simas Lt.9 Jl Fachrudin, No.18, Tanah Abang,  
Jakarta Pusat, 10250, Indonesia  
Email : klinik.lab@wapindojasaartha.id  
rgcc-indonesia@kliniksimatehat.id  
Telephone : +62 (21) 2918 9933  
WhatsApp : +62 881 0241 86881  
Website : www.kliniksimatehat.id  
📷 📱 : kliniksimatehat



## **RGCC HEADQUARTES** **RGCC International GmbH**

Address : Baarerstrasse 95, Zug,  
6300, Swiss



## **LABORATORY FACILITIES**

- Florina, Yunani
- Halle, Jerman
- Hyderabad, India
- Baar, Swiss

## **Celebrating success :**

RGCC feature as one of the Top 10 Swiss  
Biotech Companies by Life Sciences Review



**Website scan here**